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ApoA-I deficiency increases cortical amyloid
deposition, cerebral amyloid angiopathy,
cortical and hippocampal astrogliosis, and
amyloid-associated astrocyte reactivity in
APP/PS1 mice
Emily B. Button1,2, Guilaine K. Boyce3, Anna Wilkinson1,2, Sophie Stukas1,2, Arooj Hayat1, Jianjia Fan1,2,
Brennan J. Wadsworth2, Jerome Robert1,2, Kris M. Martens4 and Cheryl L. Wellington1,2*
Abstract
Background: Alzheimer’s disease (AD) is defined by amyloid beta (Aβ) plaques and neurofibrillary tangles and
characterized by neurodegeneration and memory loss. The majority of AD patients also have Aβ deposition in cerebral
vessels known as cerebral amyloid angiopathy (CAA), microhemorrhages, and vascular co-morbidities, suggesting
that cerebrovascular dysfunction contributes to AD etiology. Promoting cerebrovascular resilience may therefore be a
promising therapeutic or preventative strategy for AD. Plasma high-density lipoproteins (HDL) have several vasoprotective
functions and are associated with reduced AD risk in some epidemiological studies and with reduced Aβ deposition and
Aβ-induced inflammation in 3D engineered human cerebral vessels. In mice, deficiency of apoA-I, the primary protein
component of HDL, increases CAA and cognitive dysfunction, whereas overexpression of apoA-I from its native promoter
in liver and intestine has the opposite effect and lessens neuroinflammation. Similarly, acute peripheral administration of
HDL reduces soluble Aβ pools in the brain and some studies have observed reduced CAA as well. Here, we expand upon
the known effects of plasma HDL in mouse models and in vitro 3D artery models to investigate the interaction of
amyloid, astrocytes, and HDL on the cerebrovasculature in APP/PS1 mice.
Methods: APP/PS1 mice deficient or hemizygous for Apoa1 were aged to 12months. Plasma lipids, amyloid plaque
deposition, Aβ protein levels, protein and mRNA markers of neuroinflammation, and astrogliosis were assessed using
ELISA, qRT-PCR, and immunofluorescence. Contextual and cued fear conditioning were used to assess behavior.
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Results: In APP/PS1 mice, complete apoA-I deficiency increased total and vascular Aβ deposition in the cortex but not
the hippocampus compared to APP/PS1 littermate controls hemizygous for apoA-I. Markers of both general and vascular
neuroinflammation, including Il1b mRNA, ICAM-1 protein, PDGFRβ protein, and GFAP protein, were elevated in apoA-I-
deficient APP/PS1 mice. Additionally, apoA-I-deficient APP/PS1 mice had elevated levels of vascular-associated ICAM-1 in
the cortex and hippocampus and vascular-associated GFAP in the cortex. A striking observation was that astrocytes
associated with cerebral vessels laden with Aβ or associated with Aβ plaques showed increased reactivity in APP/PS1
mice lacking apoA-I. No behavioral changes were observed.
Conclusions: ApoA-I-containing HDL can reduce amyloid pathology and astrocyte reactivity to parenchymal and vascular
amyloid in APP/PS1 mice.
Keywords: Alzheimer’s disease, High-density lipoproteins, Apolipoprotein A-I (apoA-I), Amyloid beta, Cerebral amyloid
angiopathy, Neuroinflammation, Astrogliosis, Cerebrovasculature
Background
Alzheimer’s disease (AD) is a neurodegenerative disease
affecting 50 million people worldwide [1] with no
disease-modifying therapy [2]. Amyloid beta (Aβ) pla-
ques and neurofibrillary tangles are the neuropatho-
logical hallmarks of AD, and Aβ is the most common
target in ongoing clinical trials [2]. The majority of AD
patients have co-morbid vascular diseases and cerebro-
vascular pathologies including microinfarcts, cerebral
atherosclerosis, and arteriolosclerosis [3, 4]. Most also
have Aβ deposition in cerebral arteries, known as cere-
bral amyloid angiopathy (CAA) [5]. Promoting cerebro-
vascular resilience may therefore be an attractive
approach towards treating or preventing AD.
Plasma high-density lipoproteins (HDL) are well-estab-
lished to provide resilience to atherosclerotic cardiovas-
cular disease [6, 7]. In addition to its role in reverse
cholesterol transport, other vasoprotective functions of
HDL include promoting endothelial nitric oxide (NO)
synthase activity, reducing inflammation, and suppress-
ing vascular adhesion molecule expression [8–12]. Im-
portantly, aging and vascular disease can impair these
functions [8, 13–15]. Using a novel model of 3D bioengi-
neered human arteries, we recently identified additional
HDL functions that are directly relevant to AD patho-
genesis and involve the human cerebrovasculature. Spe-
cifically, we found that HDL circulated through the
lumen of bioengineered human arteries prevents Aβ de-
position within the bioengineered arterial wall, promotes
Aβ transport from “brain” to “blood”, and attenuates
Aβ-induced monocyte adhesion to endothelial cells both
in monoculture and in engineered arteries [16, 17].
Considerable human data support a role for HDL in re-
ducing AD risk. Two recent large genome wide associ-
ation studies (GWAS) identified gene sets for lipoprotein
metabolism and HDL components, namely APOE,
ABCA1, APOC1, APOM, APOA2, PON1, CLU, LCAT,
CETP, and APOAI, that were significantly associated with
AD risk [18, 19]. Epidemiological studies, especially those
that measure baseline high-density lipoprotein cholesterol
(HDL-C) levels at middle age, have found significant asso-
ciations between elevated plasma HDL-C levels and
reduced AD risk and memory impairments [20–27]. Al-
though other studies have found no relationship between
HDL-C and cognitive impairment [28–33], many of these
measured baseline HDL-C levels in aged subjects [32, 33]
or had a relatively short follow-up [31, 33].
Studies in mice also support a protective role for HDL in
AD pathogenesis. APP/PS1 mice lacking apoA-I
(apoA-IKO) have more CAA [34] with no significant
change in total amyloid burden [35, 36] or neuroinflamma-
tion [34]. Conversely, increasing HDL levels in Aβ overex-
pressing mice, either through transgenic overexpression or
upon treatment with an apoA-I mimetic, resulted in re-
duced CAA [37], lower amyloid plaque load [38–41], and
attenuated neuroinflammation [37–39, 41]. Others have
administrated reconstituted HDL, recombinant apoA-I,
and apoA-I mimetics to APP/PS1 or other AD model mice
and similarly observed improvements in memory, neuroin-
flammation, and CAA, and some also observed reduced
total soluble Aβ levels and Aβ deposition [39, 41–43]. In
the present study, we used APP/PS1 mice deficient or
hemizygous for apoA-I to extend these previous in vivo
studies, confirm a clear role for apoA-I on cortical CAA
and on cortical and hippocampal inflammation, and report
a novel interaction among apoA-I, astrogliosis, and vascu-
lar and parenchymal amyloid.
Materials and methods
Animals
All procedures involving animals were approved by the
Canadian Council of Animal Care and the University of
British Columbia Committee on Animal Care. APP/PS1
mice (Jackson laboratories, B6.Cg-Tg(APPswe,PSEN1dE9)
85Dbo/Mmjax, MMRRC stock no: 34832-JAX) on a
C57Bl/6 background co-express two transgenes from the
murine prion promoter: a chimeric mouse/human amyloid
precursor protein (APP) cDNA containing the Swedish
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(K670M/N671 L) mutations, and the human presenilin-1
(PS1) gene deleted for exon 9 [44]. APP/PS1 mice were first
bred with apoA-I-deficient mice with targetted disruption
in Apoa1(Jackson Laboratories, B6.129P2-Apoa1tm1Unc/J,
Stock no: 002055, also on a C57Bl/6 background) to pro-
duce an F1 generation hemizygous for both Apoa1tm1Unc
and APP/PS1 transgenes. These animals where then back-
crossed to apoA-I knockouts (homozygous for Apoa1t-
m1Unc) to produce F2 male and female mice of four
genotypes: APP/PS1 mice hemizygous for Apoa1 (APP/PS1
apoA-IHEM), APP/PS1 mice with complete Apoa1 defi-
ciency (APP/PS1 apoA-IKO), nontransgenic littermates
hemizygous for Apoa1 (WT apoA-IHEM), and nontrans-
genic littermates deficient in Apoa1 (WT apoA-IKO). Al-
though APP/PS1 mice on a pure C57Bl/6 background have
an increased seizure risk, we selected this strain to maintain
genetic homogeneity throughout this breeding strategy.
Overall, 80% of the animals survived until the end of the
experiment, with specific survival rates of 66% for APP/PS1
mice, 63% for APP/PS1 apoA-IHEM mice, and 74% for
APP/PS1 apoA-IKO mice (Additional file 1: Figure S1a and
b). While this breeding strategy was successful in generat-
ing N = 6–8 mice per group, insufficient animals survived
to yield sex-specific cohorts. We therefore used mixed
sexes, which is an acknowledged limitation of this study,
yet tracking of individual animals throughout the study
showed no clear sex bias throughout the results and justi-
fies the use of pooled sexes.
Tissue collection
Mice were fasted for 4 h prior to anesthetization by intra-
peritoneal injection of 20mg/kg xylazine (Bayer) and 150
mg/kg ketamine (Bimeda-MTC). Blood was collected by
cardiac puncture in ethylenediaminetetraacetic acid
(EDTA)-containing syringes, centrifuged at 21,000g for 10
min at 4 °C, and the resulting plasma was stored at − 80 °C
until use. Mice were then perfused for 6min with ice-cold
phosphate-buffered saline (PBS) containing 2500U/L hep-
arin at 6mL/min. Brains were excised and bisected in the
sagittal plane. A 2 × 5 mm piece of parietal cerebral cortex
was removed and stored separately for RNA analysis. The
piece of brain for RNA analysis and the remaining
half-brain were snap-frozen on dry ice and stored at − 80 °
C until use. The remaining half-brain was fixed in 4%
paraformaldehyde (PFA) for 2 days at 4 °C followed by
storage in PBS containing 30% sucrose and 0.1% sodium
azide at 4 °C.
Plasma lipid measurements
Plasma HDL cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and total cholesterol levels were mea-
sured using Wako kits (Category no: 997-01301 for
HDL-C, 993-00404 and 999-00504 for LDL-C, and 999-
02601 for total cholesterol) as per the manufacturer’s
directions adapted for 96-well microplates. Plasma samples
were randomized, and the researcher performing the mea-
surements was blinded to sample genotype. Plasma lipids
were analyzed in N = 6–7 mice per genotype.
Histology
Immunofluorescence triple co-staining was performed to
visualize endothelial cells (cluster of differentiation 31;
CD31), amyloid beta plaques (X-34), and activated astro-
cytes (glial fibrillary acidic protein; GFAP) as follows. Cryo-
protected half brains were sectioned at 40 μm on a Leica
CM3050 Research Cryostat and stored in PBS containing
0.1% sodium azide until staining. Three sections from each
half-brain were selected from the anterior to posterior
hippocampus at 200-μm intervals and mounted on Super-
frost Plus slides. Antigen retrieval was performed with cit-
rate buffer (10mM citric acid, 0.05% Tween 20, pH 6.0) at
95 °C for 5min followed by washing with PBS, tissue
permeabilization with 0.25% Triton X-100 in PBS for 30
min, and blocking with 5% donkey serum and 1% BSA and
0.3% Triton X-100 in PBS for 60min. Sections were incu-
bated in primary antibodies for CD31 (Abcam, ab28364,
1:200 dilution), GFAP Alexa Fluor 488 (eBiosceince,
53-9892-80 1:400 dilution), or ICAM-1 (R&D, AF796, 1:50
dilution) in 5% donkey serum, 1% BSA, and 0.3% Triton
X-100 in PBS overnight at 4 °C. After washing with PBS,
sections were incubated with secondary antibodies for 60
min at room temperature. Secondary antibodies were as
follows: goat anti-rabbit Alexa Fluor 594 antibody (Life
Tech, A11012, 1:600 dilution) to detect CD31 on its own
and when co-stained with GFAP, goat anti-rabbit Alexa
Fluor 647 antibody (Life Tech, A27040, 1:400 dilution) to
detect CD31 co-stained with ICAM-1, and donkey
anti-goat Alexa Fluor 594 antibody (Life Tech, A-11058,
1:400 dilution) to detect ICAM-1. Sections were then
washed with PBS. Amyloid staining was subsequently per-
formed with X-34 (Sigma-Aldrich, SML 1954, 2 μM in
PBS-T) for 20–30min followed by washing with 40% etha-
nol in PBS then PBS alone. Coverslips were mounted onto
slides in prolong antifade (Invitrogen, P36970), and slides
were stored at 4 °C until imaging with an Axio Scan.Z1
(Zeiss). Brain sections were randomized, and the re-
searcher performing the staining was blinded to sample
genotype. The cellular localization of ICAM-1 expression
was visualized using an LSM 880 confocal laser scanning
microscope (Zeiss).
Image analysis
Image analysis was performed with ImageJ (NIH) by a
researcher blinded to sample genotype as illustrated in
Additional file 1: Figure S2. Exported images for each
channel were converted to 8-bit black and white images.
The threshold for positive and negative pixels was
manually determined for X-34 and GFAP images using
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histogram-based segmentation then applied to all of the
images of that channel. Due to regional variation in
CD31 staining, auto-local thresholding using the Bern-
sen method was performed on CD31 images. Cortical
and hippocampal regions were manually selected and
saved as “regions of interest” (ROIs) for each section.
Total CD31, X-34, and GFAP-positive area was mea-
sured in the threshold segmented cortical and hippo-
campal ROIs and normalized to the total ROI area.
Vascular GFAP was quantified as the GFAP-positive area
associated with CD31 in each region whereby a mask of
the segmented CD31 image for a section was created
then applied to the segmented GFAP image of the same
section. The GFAP-positive area within the CD31 mask
was measured then normalized to the total CD31-posi-
tive area within the ROI. Plaque-associated GFAP was
similarly quantified as the GFAP-positive area associated
with X-34 in each region whereby a mask of the seg-
mented X-34 image for a section was created then ap-
plied to the segmented GFAP image of the same section.
The GFAP-positive area within the X-34 mask was mea-
sured then normalized to the total X-34-positive area
within the ROI.
Total and vascular ICAM-1 quantification was per-
formed using the same techniques as described above to
measure total and vascular GFAP. Parenchymal ICAM-1
-positive area was calculated as the difference between
total and vascular ICAM-1-positive area in the cortical
and hippocampal regions.
CAA was quantified using methods similar to that pub-
lished in Nature Protocols by Wilcock et al. in 2006 [45],
which has been used by many others [37, 46, 47] including
in the study by Lefterov et al. using apoA-I-deficient APP/
PS1 mice [34]. A mask containing areas of vascular amyl-
oid was created by manually discriminating vascular amyl-
oid from parenchymal plaques in segmented X-34 images
based on morphology, as illustrated in Additional file 1:
Figure S3. Identification of vascular versus parenchymal
amyloid was performed on inverted images to ease
visualization. These vascular amyloid masks were then ap-
plied back onto segmented X-34 images, and the percent
positive area was measured and normalized to total area of
the cortical ROI to give percent cortical CAA area. The
X-34-positive area within the vascular amyloid mask was
then used to create a new CAA mask. This CAA mask was
then applied to a mask of vascular GFAP created as above.
The vascular GFAP-positive area within the CAA mask
was measured and normalized to CAA area to give the
percent area of CAA associated with vascular GFAP.
The above analysis steps, excluding the drawing of cor-
tical and hippocampal ROIs and vascular amyloid areas,
were repeated for each section using an automated ImageJ
macro. The full macro text for the imaging strategy is
available in Additional file 2. Additional file 1: Figure S2
shows schematics illustrating the image analysis process.
Analysis of vessel diameter and tortuosity was performed
with Vesselucida 360 software (MBF Bioscience) using
CD31 as the vessel marker. For amyloid staining, N = 4–5
animals per genotype were used, and for CD31, GFAP,
and ICAM-1 staining, N = 5–6 animals per genotype were
used.
Protein extraction
Protein from half-brains was serially extracted to produce
soluble and insoluble protein fractions. Half-brains were
first homogenized with a Tissuemite homogenizer for 20 s
in carbonate buffer (10mmol/L carbonate, 50mmol/L so-
dium chloride, cOmplete protease inhibitor tablet, pH
11.5) then sonicated. Homogenates were cleared by centri-
fugation at 12,500g for 45min at 4 °C. The resulting super-
natant was neutralized with 1.5 volumes Tris (1mol/L
Tris, pH 6.8) and labeled as the soluble fraction. The pellet
was resuspended in 1mL of guanidine hydrochloride (5
mol/L guanidine hydrochloride in 1mol/L Tris, pH 8.0) by
pipetting followed by rotation overnight at room
temperature and labeled as the insoluble fraction. Soluble
and insoluble extracts were stored at − 80 °C until use.
Lysate protein concentrations were determined using the
DC Protein assay kit (BioRad).
Elisa
Human Aβ40 (KHB-3482, ThermoFisher, 1:20, 1:2500),
human Aβ42 (KHB-3442, ThermoFisher, 1:40, 1:2500),
and murine apoE (3752-1HP-2, ThermoFisher, 1:20,
1:200) levels were measured in carbonate soluble and
guanidine hydrochloride insoluble half-brain lysates
using commercial sandwich ELISA kits according to the
manufacturer’s instructions. Murine GFAP (NS830,
Millipore, 1:400), intercellular adhesion molecule 1
(ICAM-1) (ab100688, Abcam, 1:2), vascular cell adhe-
sion molecule (VCAM-1) (ab100750, Abcam, 1:2000),
platelet-derived growth factor receptor beta (PDGFRβ)
(MBS919047, MyBioSource, 1:10), interleukin 1 beta
(IL-1β) (K15245D, MesoScale Discovery, 1:2), and tau
(K15121D, MesoScale Discovery, 1:50) levels were mea-
sured in carbonate soluble half-brain lysates using com-
mercial sandwich or MesoScale Discovery ELISA kits
according to the manufacturer’s instructions. Data points
were interpolated from a standard curve using a
4-parameter nonlinear regression curve fitting and nor-
malized to total soluble protein concentration. Brain ly-
sates were randomized and the researcher performing
the ELISAs was blinded to sample genotype. For apoE
ELISA, N = 6 mice per genotype were used. For Aβ
ELISA, N = 5–7 mice per genotype were used. For IL-1β,
ICAM-1, VCAM-1, and PDGFRβ ELISA, N = 5–19 mice
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per genotype were used. For GFAP ELISA, N = 6–14
mice per genotype were used.
RNA isolation and RT-qPCR
RNA was extracted from parietal cerebral cortices using
Trizol (Invitrogen) and treated with DNaseI (Life Technolo-
gies) prior to cDNA synthesis. cDNA was generated using
the Taqman Reverse Transcription Kit (ThermoFisher,
N8080234). RT-qPCR was performed using the Light Cy-
cler 96 Real-Time PCR System (Roche) and FastStart Es-
sential DNA Green Master Mix (Roche). Expression of
murine Abca1 (Fwd: CTGACCTATGTGCTGCCGTA;
Rev.: GAGCCGGTCATCAATCTCAT) and murine Il1b
(Fwd: TTGACGGACCCCAAAAGA; Rev.: CAGCTTCTC
CACAGAGCCACA) were normalized to murine β-actin
(Fwd: ACGGCCAGGTCATCACTATTG; Rev.: CAAG
AAGGAAGGCTGGAAAAG). RNA homogenates were
randomized, and the researcher performing the qRT-PCR
was blinded to sample genotype. For Apoe and Il1b mRNA
analyses, N = 7–12 mice per genotype were used.
Contextual and cued fear conditioning
Training
During training, mice were placed in an illuminated
compartment of a shuttle box (Med Associates Inc., St.
Albans, VT) and allowed to habituate to the internal
testing environment for 120 s. After the habituation
period, an 80-dB auditory cue was played for 30 s. Dur-
ing the last 2 s of the auditory cue, a mild foot shock
(0.3 mA) was administered. Shocked mice were left
undisturbed in the testing chamber for an inter-trial
interval (ITI) of 60 s, after which mice were presented
with a second identical tone, which was called the shock
trial. After the second tone, shocked mice were again left
undisturbed in the testing chamber for 60 s.
Context testing
Twenty-four hours after training, mice were tested for
their ability to remember the context in which they re-
ceived the foot shock. Mice were placed in the same illu-
minated compartment and observed for the presence/
absence of a freezing response over 5 min. During this
time, mice were not exposed to the tone or shock and the
percent freezing time was measured using the ANY-Maze
system (Stoelting Co., Wood Dale, IL). Contextual testing
included N = 7–23 mice per genotype.
Cued testing
One hour following context testing, mice were tested for
their ability to remember the 80-dB auditory cue pre-
sented during the training session. Testing was conducted
in an environment different from the training and context
testing session (darkened compartment, false floor placed
over the steel rods of the shuttle box, different cleaning
solution). Mice were placed in the darkened compartment
and allowed to habituate for 120 s, followed by the 80 dB
auditory cue for 120 s. After the tone, mice were left un-
disturbed in the testing chamber for 60 s and percent
freezing time was measured using the ANY-Maze system.
Cued testing included N = 7–23 mice per genotype.
Statistical analysis
All statistical analyses were performed with GraphPad
Prism 7; p values < 0.05 were considered statistically sig-
nificant. For the analysis of all non-amyloid data, statistical
comparisons were made by two-way ANOVA considering
APP/PS1 genotype as one factor and apoA-I genotype as a
second factor (omnibus analysis) followed by Sidak’s mul-
tiple comparisons test if significant factor or interaction
effects were observed. Analysis of Aβ levels, amyloid
plaque area, and CAA were performed with unpaired t
test or Mann-Whitney test for parametric and non-para-
metric data, respectively.
Results
Loss of apoA-I significantly reduces plasma total and HDL
cholesterol levels
By omnibus two-way ANOVA, apoA-I deficiency signifi-
cantly reduced plasma total cholesterol (p = 0.013),
HDL-C (p < 0.0001), and LDL-C levels (p = 0.048)
(Fig. 1a–c) relative to apoA-IHEM mice, as previously re-
ported [48, 49]. HDL-C was the cholesterol pool most af-
fected by the complete loss of apoA-I with reductions
from 48.3mg/dL to 14.6mg/dL (p = 0.011) in WT
apoA-IKO vs. WT apoA-IHEM mice and from 50.1mg/dL
to 8.3mg/dL (p = 0.003) in APP/PS1 apoA-IKO vs. APP/
PS1 apoA-IHEM mice. Plasma cholesterol pools were not
affected by APP/PS1 genotype. ApoA-I genotype did not
affect soluble (Fig. 1d) or insoluble (Fig. 1e) brain apoE
protein levels or cortical Apoe mRNA expression (Fig. 1f),
although insoluble apoE protein levels in the brain were
significantly higher in APP/PS1 mice compared to WT
controls overall (p < 0.0001) (Fig. 1e).
ApoA-I deficiency increases cortical parenchymal and
vascular amyloid burden of APP/PS1 mice
Histological examination of X-34-stained sections
showed that apoA-I deficiency led to significantly greater
amyloid burden in the cortex, an increase from a mean
of 0.28% to 0.91% cortical area (Fig. 2a, b) (p = 0.001 by
unpaired t test), but not in the hippocampus (Fig. 2c, d)
of APP/PS1 mice. Consistent with a previous study [34],
we also observed significantly increased cortical CAA
from a mean of 0.01% to 0.05% cortical area in APP/PS1
apoA-IKO compared to APP/PS1 apoA-IHEM mice (p =
0.016 by Mann-Whitney test) (Fig. 2e, f ). CAA was not
observed in the hippocampus in any mice. These obser-
vations suggest that apoA-I protects against Aβ
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deposition in the walls of cortical arteries, which may in
turn reduce parenchymal amyloid deposition in the sur-
rounding cortex.
Biochemical analysis of total soluble and insoluble Aβ40
and Aβ42 pools in half-brain homogenates revealed no dif-
ferences by apoA-I genotype, although soluble Aβ40, insol-
uble Aβ40, and insoluble Aβ42 were all very slightly and
non-significantly increased in APP/PS1 apoA-IKO vs. APP/
PS1 apoA-IHEM mice (Fig. 2g–j). The lack of a significant
effect of apoA-I genotype on Aβ levels, despite the signifi-
cant increase in cortical amyloid deposition, may be due to
a region-specific effect of apoA-I on amyloid that is not de-
tectable in crude half-brain homogenates. Indeed, im-
munofluorescence analysis (described above) confirms that
apoA-I genotype influences amyloid plaque burden in the
cortex but not in the hippocampus.
Although no significant differences in tau or p-tau were
observed by APP/PS1 genotype, total tau levels (Fig. 2k)
were significantly higher and p-tau levels (Fig. 2l) tended
to be higher in apoA-IKO mice compared to apoA-IHEM
mice (p = 0.041 and p = 0.054, respectively, by omnibus
two-way ANOVA). ApoA-I genotype significantly inter-
acted with APP/PS1 genotype with respect to p-tau (p =
0.023). Post-hoc Sidak’s multiple comparison tests revealed
a nearly significant increase in total tau in APP/PS1
apoA-IKO vs. APP/PS1 apoA-IHEM mice (p = 0.063) and a
significant increase in p-tau from 1.09 ng/mg in APP/PS1
apoA-IKO to 1.40 ng/mg in APP/PS1 apoA-IHEM (p =
0.026). Levels of p-tau showed a trend towards a reduction
in APP/PS1 apoA-IHEM vs. WTapoA-IHEM mice (p = 0.099
by Sidak’s multiple comparisons test). The total tau to
p-tau ratio was unaffected by loss of apoA-I (Fig. 2m).
ApoA-I deficiency increases cortical levels of pro-
inflammatory protein and mRNA markers in APP/PS1 mice
IL-1β protein levels in half-brain homogenates were ele-
vated in APP/PS1 compared to WT mice from a mean of
0.36 pg/mg and 0.42 pg/mg in WT apoA-IHEM and
apoA-IKO, respectively, to 0.79 pg/mg and 0.82 pg/mg in
APP/PS1 apoA-IHEM and apoA-IKO, respectively, (p <
0.0001 by omnibus two-way ANOVA). IL-1β protein levels
were not affected by apoA-I genotype (Fig. 3a). However,
cortical Il1b mRNA levels were significantly elevated over-
all in APP/PS1 compared to WT mice (p < 0.0001 omnibus
by two-way ANOVA) and in apoA-IKO vs. apoA-IHEM mice
(p = 0.009 by omnibus two-way ANOVA) (Fig. 3b), where
the mean expression ratio was 5.37e-11 in WTapoA-IHEM,
1.06e-10 in WT apoA-IKO, 1.51e-10 in APP/PS1
apoA-IHEM, and 2.17e-10 in APP/PS1 apoA-IKO. The dis-
crepancy between IL-1β protein and mRNA observations
may be due to both the lower limit of sensitivity for the
protein assay and regional selectivity. Brain protein and
mRNA expression of TNFα and IL-6 were also measured
but were all below limits of detection (data not shown).
We next investigated markers of inflammation
expressed specifically by cells of the blood-brain barrier.
a b c
d e f
Fig. 1 Loss of apoA-I significantly reduced plasma cholesterol levels. Plasma levels of (a) total cholesterol, (b) HDL-C, and (c) LDL-C were measured with
commercially available kits. ApoE protein in (d) soluble and (e) insoluble half-brain homogenates was measured by ELISA. f ApoemRNA expression was
measured in the parietal cerebral cortex by qRT-PCR. Points represent individual mice and bars represent mean values. Circles represent female mice, and
squares represent male mice. Omnibus analyses of apoA-I and APP/PS1 genotype effects by two-way ANOVA are displayed as exact p values below
graphs. Sidak’s multiple comparisons test results are displayed within graphs as *p< 0.05, **p< 0.01, and ***p< 0.0001. For plasma lipid and brain protein
analysis, N= 6–7 mice per genotype; for mRNA analysis N= 7–17 mice per genotype were used. apoA-I, apolipoprotein A-I; TC, total cholesterol; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HEM, hemizygous apoA-I genotype; KO, knockout apoA-I genotype; WT,
wildtype APP/PS1 genotype; APP/PS1, transgenic APP/PS1 genotype; apoE, apolipoprotein E
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PDGFRβ is a pericyte marker that is elevated in some
cases of neuroinflammation [50]. We observed a signifi-
cant interaction effect of APP/PS1 and apoA-I genotypes
(p = 0.026 by omnibus two-way ANOVA) on PDGFRβ
protein levels in the brain, where PDGFRβ protein tended
to be elevated only in APP/PS1 apoA-IKO mice compared
to APP/PS1 apoA-IHEM mice (p = 0.065 by Sidak’s
multiple comparisons test) (Fig. 3c). Mean PDGFRβ levels
were 5.03 ng/mg in WT apoA-IHEM, 4.56 ng/mg in WT
apoA-IKO, 3.76 ng/mg in APP/PS1 apoA-IHEM, and 5.61
ng/mg in APP/PS1 apoA-IKO. To evaluate endothelial
cell-specific inflammation, we measured protein levels of
VCAM-1 in the brain. VCAM-1 is expressed on the cell






Fig. 2 Cortical amyloid plaques and vascular Aβ deposition were increased the absence of apoA-I. Total (a, b) cortical and (c, d) hippocampal area
occupied by amyloid deposits and (e, f) CAA area were evaluated by staining fixed cryosections with X-34. Representative images are below graphs. g
Soluble Aβ40, h soluble Aβ42, i insoluble Aβ40, and j insoluble Aβ42 protein levels were measured in half-brain homogenates by ELISA. k Total tau and l
phosphorylated tau proteins were measured by ELISA and used to calculate the (m) phosphorylated tau/total tau ratio. All analytes were normalized to
homogenate total protein concentration. Points represent individual mice, and bars represent mean values. Circles represent female mice, and squares
represent male mice. Arrowheads in f indicate areas of CAA. Results of unpaired t test (a) and Mann-Whitney test (e) are displayed within graphs as *p<
0.05 and **p< 0.01. Omnibus analyses of apoA-I and APP/PS1 genotype effects by two-way ANOVA are displayed as exact p values below graphs (k, l).
Sidak’s multiple comparisons test results (l) are displayed within the graph as *p< 0.05. For amyloid staining, N= 4–5 mice per genotype were used; for Aβ
ELISA, N= 5–7 mice per genotype were used; for tau and p-tau ELISA, N= 6–19 mice per genotype were used. apoA-I, apolipoprotein A-I; HEM,
hemizygous apoA-I genotype; KO, knockout apoA-I genotype; WT, wildtype APP/PS1 genotype; APP/PS1, transgenic APP/PS1 genotype; CAA, cerebral
amyloid angiopathy; Aβ, amyloid beta; p-tau, phosphorylated tau; X-34, amyloid stain
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circulating immune cells to the vessel wall [11]. We
found that VCAM-1 tended to be elevated in
apoA-IKO mice compared to apoA-IHEM mice overall
(p = 0.076 by omnibus two-way ANOVA) independent
of APP/PS1 genotype (Fig. 3d). Together, these data
suggest that loss of apoA-I can exacerbate neuroin-
flammation in APP/PS1 mice, particularly in cell types
associated with the cerebrovasculature.
ApoA-I deficiency increases total ICAM-1 protein levels in
the brain, total ICAM-1 positive area in the hippocampus,
and vascular ICAM-1 levels in the cortex and
hippocampus of APP/PS1 mice
ICAM-1 is another endothelial cell adhesion molecule
that functions similarly to VCAM-1. ICAM-1 can also be
expressed in other cells such as astrocytes and microglia
[51–54]. We observed an overall effect of apoA-I genotype
on brain ICAM-1 levels with increased levels in apoA-IKO
mice (p = 0.013 by omnibus two-way ANOVA), a specific
increase in APP/PS1 apoA-IKO mice compared to APP/
PS1 apoA-IHEM mice from a mean of 0.72 ng/mg to 1.25
ng/mg (p = 0.023 by Sidak’s multiple comparisons test),
and a trend towards a significant interaction effect be-
tween apoA-I and APP/PS1 genotypes (p = 0.079 by omni-
bus two-way ANOVA) (Fig. 4a). Confocal imaging
confirmed co-localization of ICAM-1 with CD31 (Fig. 4b)
and showed that only some of the parenchymal ICAM-1
was co-localized with GFAP-positive astrocytes, suggest-
ing expression by other cell types (Fig. 4c).
The effect of apoA-I genotype on total brain ICAM-1
levels was found to be region specific using immuno-
fluorescence. Although we observed no significant differ-
ences in total cortical ICAM-1 staining by apoA-I
genotype (Fig. 4b), total ICAM-1-positive area was
increased in APP/PS1 apoA-IKO compared to APP/PS1
apoA-IHEM in the hippocampus, from 2.34% of hippo-
campal area to 4.67% (p = 0.001 by Sidak’s multiple com-
parisons test) (Fig. 4c). Interestingly, vascular-specific
ICAM-1, measured as the ICAM-1-positive area associ-
ated with CD31, was significantly elevated in both cortex
(Fig. 4d, e) and hippocampus (Fig. 4f, g) in APP/PS1
a b
c d
Fig. 3 Cortical levels of pro-inflammatory protein and mRNA markers were increased in the absence of apoA-I. a IL-1β, c PDGFRβ, and d VCAM-1 protein
levels were measured by ELISA in soluble half-brain homogenates; values were normalized to total protein concentration in the homogenates. b Il1b
mRNA expression was measured in the cortex by qRT-PCR and normalized to β-actin expression. Points represent individual mice, and bars represent
mean values. Circles represent female mice, and squares represent male mice. Omnibus analyses of apoA-I and APP/PS1 genotype effects by two-way
ANOVA are displayed as exact p values below graphs. Sidak’s multiple comparisons test results are displayed within graphs as *p< 0.05, ***p< 0.001, and
****p< 0.0001. For ELISA, N= 5–19 mice per genotype were used; for mRNA, N= 7–21 mice per genotype were used. apoA-I, apolipoprotein A-I; HEM,
hemizygous apoA-I genotype; KO, knockout apoA-I genotype; WT, wildtype APP/PS1 genotype; APP/PS1, transgenic APP/PS1 genotype; IL-1β, interleukin 1
beta; VCAM-1, vascular cell adhesion molecule 1; PDGFRβ, platelet-derived growth factor receptor beta
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apoA-IKO compared to APP/PS1 apoA-IHEM. Cortical
vascular ICAM-1 levels were 7.87% and 12.26% of
CD31-positive area in APP/PS1 apoA-IHEM and APP/
PS1 apoA-IKO, respectively (p = 0.001 by Sidak’s mul-
tiple comparisons test) (Fig. 4h, j) and hippocampal
levels were 15.02% and 24.19% (p = 0.001 by Sidak’s
multiple comparisons test) (Fig. 4k,m). Although no
differences in parenchymal ICAM-1-positive area were
observed in the absence of apoA-I (Fig. 4i, j), paren-
chymal ICAM-1-positive area was increased in the
hippocampus from 2.19% of hippocampal area in
APP/PS1 apoA-IHEM to 4.41% in APP/PS1 apoA-IKO
(p = 0.001 by Sidak’s multiple comparisons test)
(Fig. 4l, m).
a b c
d e f g
h i k l
j m
Fig. 4 Absence of apoA-I increases ICAM-1 protein levels, hippocampal parenchymal ICAM-1 levels, and both cortical and hippocampal endothelial ICAM-
1 levels. a Total ICAM-1 protein in soluble half-brain homogenates was measured by ELISA. Confocal microscopy was used to (b) identify co-localization of
ICAM-1 with the endothelial cell marker CD31 and (c) evaluate the co-localization of some ICAM-1 in the brain parenchyma with GFAP-positive astrocytes.
Total ICAM-1 staining area was visualized by immunofluorescence in cortical (d, e) and hippocampal (f, g) regions and positive staining area was
normalized to total region area (h, j, k,m). Vascular-specific and parenchymal ICAM-1 expression was visualized using immunofluorescence and shows
association of GFAP with CD31 in (h–j) cortical and (k–m) hippocampal regions, where positive co-stained area was normalized to total CD31-positive area.
Representative images for immunofluorescent data are below the graphs. Points represent individual mice, and bars represent mean values. Circles
represent female mice, and squares represent male mice. Omnibus analyses of apoA-I and APP/PS1 genotype effects by two-way ANOVA are displayed as
exact p values below graphs. Sidak’s multiple comparisons test results are displayed within graphs as *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001.
For ELISA, N= 6–19 mice per genotype were used. apoA-I, apolipoprotein A-I; HEM, hemizygous apoA-I genotype; KO, knockout apoA-I genotype; WT,
wildtype APP/PS1 genotype; APP/PS1, transgenic APP/PS1 genotype; ICAM-1, intercellular adhesion molecule 1; GFAP, glial fibrillary acidic protein; CD31,
cluster of differentiation 31. Green closed arrowheads indicate examples of vascular ICAM-1, and white open arrowheads indicate examples of
parenchymal ICAM-1
Button et al. Alzheimer's Research & Therapy           (2019) 11:44 Page 9 of 18
ApoA-I deficiency exacerbates Aβ-mediated increases in
total and cerebrovascular GFAP levels in both cortex and
hippocampus
We observed a significant interaction effect between APP/
PS1 and apoA-I genotypes on total GFAP protein levels in
half-brain homogenates (p = 0.007 by omnibus two-way
ANOVA). GFAP was elevated both in APP/PS1 mice com-
pared to WT controls overall (p < 0.0001 by omnibus
two-way ANOVA) and in APP/PS1 apoA-IKO compared to
APP/PS1 apoA-IHEM mice (p = 0.030 by post-hoc Sidak’s
multiple comparisons test) (Fig. 5a). Mean GFAP protein





Fig. 5 Loss of apoA-I increased the reactivity of astrocytes associated with the cerebrovasculature. a Total GFAP protein levels were measured in soluble
half-brain homogenates by ELISA, and values were normalized to total protein concentration in the homogenates. GFAP staining area was visualized by
immunofluorescence in cortical (b, c) and hippocampal (d, e) regions, and positive staining area was normalized to total region area. Vascular-specific
GFAP expression was visualized using immunofluorescence and observing the association of GFAP with CD31 in cortical (f, g) and hippocampal (h, i)
regions, positive co-stained area was normalized to total CD31-positive area. Representative images for immunofluorescent data are below graphs. Points
represent individual mice, and bars represent mean values. Circles represent female mice, and squares represent male mice. Yellow arrowheads indicate
examples of areas of CD31-associated GFAP in the cortex (g) and hippocampus (i) that are quantified in (f) and (h), respectively. Omnibus analyses of
apoA-I and APP/PS1 genotype effects by two-way ANOVA are displayed as exact p values below graphs. Sidak’s multiple comparisons test results are
displayed within graphs as *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001. For GFAP ELISA, N= 6–14 mice per genotype were used; for GFAP total
and vascular staining, N= 5–6 mice per genotype were used. apoA-I, apolipoprotein A-I; HEM, hemizygous apoA-I genotype; KO, knockout apoA-I
genotype; WT, wildtype APP/PS1 genotype; APP/PS1, transgenic APP/PS1 genotype; GFAP, glial fibrillary acidic protein; CD31, cluster of differentiation 31
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WT apoA-IKO, 25.75 μg/mg in APP/PS1 apoA-IHEM, and
30.59 μg/mg in APP/PS1 apoA-IKO. Immunofluorescent
staining for GFAP confirmed the biochemical total protein
data, with an additive effect of Aβ overexpression and
apoA-I loss on GFAP staining area in the cortex (p = 0.001
for APP/PS1 vs. WT omnibus two-way ANOVA analysis;
p = 0.001 for APP/PS1 apoA-IKO vs. WT apoA-IKO; and p
= 0.040 for APP/PS1 apoA-IKO vs. APP/PS1 apoA-IHEM by
post-hoc Sidak’s multiple comparisons test) (Fig. 5b, c) and
a synergistic effect in the hippocampus (p = 0.008 inter-
action effect by omnibus two-way ANOVA; p = 0.004 for
APP/PS1 apoA-IKO vs. WT apoA-IKO; and p = 0.004 for
APP/PS1 apoA-IKO vs. APP/PS1 apoA-IHEM by Sidak’s
multiple comparisons test) (Fig. 5d, e). Cortical GFAP-posi-
tive area increased from 0.07% and 0.06% in WT
apoA-IHEM and apoA-IKO, respectively, to 0.70% in APP/
PS1 apoA-IHEM and 1.66% in APP/PS1 apoA-IKO. In the
hippocampus, GFAP-positive area was 2.27%, 1.77%,
1.65% and 4.28% in WT apoA-IHEM, WT apoA-IKO, APP/
PS1 apoA-IHEM, and APP/PS1 apoA-IKO respectively.
We next used immunofluorescence to examine the as-
sociation of CD31 and GFAP and observed a robust and
statistically significant increase in the cerebrovascular
area associated with GFAP in both the cortex and hippo-
campus of APP/PS1 apoA-IKO mice compared to APP/
PS1 apoA-IHEM mice (p = 0.008, p = 0.007, respectively,
by Sidak’s multiple comparisons test) (Fig. 5f–i). In
addition, significant elevations were observed overall in
APP/PS1 compared to WT mice (p < 0.0001 in the
cortex by omnibus two-way ANOVA) and in apoA-IKO
compared to apoA-IHEM mice (p = 0.025 and p = 0.049 in
the cortex and hippocampus, respectively, by omnibus
two-way ANOVA). Mean cortical vascular GFAP levels
were elevated from 0.21% and 0.30% of
CD31-positive vascular area in WT apoA-IHEM and
apoA-IKO, respectively, to 1.80% in APP/PS1 apoA-IHEM
mice and 3.86% in APP/PS1 apoA-IKO. In the hippocam-
pus, mean vascular GFAP levels increased from 6.86%,
6.20%, and 5.20% in WT apoA-IHEM, WT apoA-IKO, and
APP/PS1 apoA-IHEM, respectively, to 10.86% in APP/PS1
apoA-IKO. Strikingly, the elevation in vascular GFAP in
apoA-IKO mice was statistically more robust than the
changes in total GFAP-positive area in both the cortex
and the hippocampus. The total vascular area vessel
thickness, and vessel tortuosity as defined by CD31
staining were all unchanged by apoA-I genotype in the
cortex and the hippocampus (Additional file 1: Figure
S4a-h).
A closer examination of APP/PS1 mice revealed sig-
nificantly greater levels of cortical plaque-associated
GFAP in APP/PS1 apoA-IKO compared to APP/PS1
apoA-IHEM, which increased from a mean of 0.02% to
0.51% of plaque area (p = 0.030 by Mann-Whitney test)
(Fig. 5a, b), suggesting that apoA-I deficiency promotes
astrocyte reactivity to Aβ plaques. Parenchymal plaque-
associated GFAP was not significantly affected by
apoA-I genotype in hippocampus (Fig. 6c, d). We also
investigated whether astrocyte reactivity was affected by
CAA, and observed a significant elevation of GFAP area
on CAA-positive vessels from 0.17% of CAA area on
average in APP/PS1 apoA-IKO mice compared to 2.67%
in APP/PS1 apoA-IHEM controls (p = 0.023 by unpaired t
test) (Fig. 6e, g). Notably, this effect was larger in magni-
tude than the increases in either CAA levels or vascular
GFAP expression alone in APP/PS1 apoA-IKO mice
compared to APP/PS1 apoA-IHEM mice. Finally, we ob-
served a trend towards increased CAA in the areas of
vascular GFAP expression 0.04% of vascular GFAP area
on average in APP/PS1 apoA-IKO mice compared to
0.54% in APP/PS1 apoA-IHEM controls (p = 0.116 by
unpaired t test) (Fig. 6f, g). Taken together, our data sup-
port an interaction among Aβ, astrogliosis, and apoA-I.
ApoA-I deficiency does not significantly affect contextual
or cued fear memory
Others have observed that genetically altering apoA-I
levels in APP/PS1 mice affects spatial learning and mem-
ory, with increased apoA-I improving performance and
loss of apoA-I worsening performance in the Morris
Water Maze [34, 37]. We performed contextual and cued
fear conditioning tests to evaluate fear memory (Add-
itional file 1: Figure S5a and b). No significant genotype ef-
fects were observed with either test despite a trend
towards reduced performance in both APP/PS1 vs. WT
mice (p = 0.109) and in apoA-IKO vs. apoA-IHEM mice (p
= 0.077) overall in the contextual fear conditioning test.
Notably, the cohort of mice available for behavior testing
was relatively small, particularly for the APP/PS1
apoA-IKO group (n = 7); therefore, our behavior analysis
was likely underpowered.
Discussion
A better understanding of the vascular contributions to AD
may reveal attractive therapeutic targets that act systemic-
ally and therefore may not necessarily need to cross the
blood-brain barrier to have beneficial effects on the brain.
Circulating factors such as HDL, which has multiple vaso-
protective properties, could promote cerebrovascular health
by acting on the luminal side of cerebral vessels. We there-
fore aimed to confirm and extend previous findings by us
and others on the role of apoA-I on AD pathology in mice.
In agreement with Lefterov et. al. [34], here, we observed
that complete loss of apoA-I increases CAA in APP/PS1
mice. We also show for the first time that eliminating
apoA-I in APP/PS1 mice increases total cortical Aβ depos-
ition and astrogliosis in both the cortex and hippocampus.
Additionally, we observed that loss of apoA-I increased sev-
eral markers neuroinflammation and vascular inflammation







Fig. 6 (See legend on next page.)
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within the brain. Specifically, brain levels of Il1b mRNA,
ICAM-1 protein, PDGFRβ protein, and GFAP protein were
elevated in the absence of apoA-I. Furthermore, apoA-IKO
mice showed elevated levels of ICAM-1 on endothelial cells
and GFAP-positive astrocytes in direct contact with the cer-
ebrovasculature in the cortex and hippocampus. While Lef-
terov et al. did not observe changes in amyloid pathology
or neuroinflammation in apoA-IKO mice, other groups have
increased apoA-I levels in APP/PS1 mice using transgenic
overexpression of apoA-I or by injecting apoA-I mimetics
and observed reduced cerebral amyloid and astrogliosis [37,
39–41, 43]. Finally, we found that astrocyte reactivity to
both parenchymal and vascular amyloid was increased in
apoA-I-deficient mice. Importantly, the previous study by
Lefterov et al. using compared APP/PS1 apoA-IKO mice to
APP/PS1 apoA-IWT mice whereas the current work com-
pares APP/PS1 apoA-IKO mice to APP/PS1 apoA-IHEM
mice. Although others have shown that there is a greater
difference in plasma apoA-I levels between apoA-IKO and
apoA-IHEM mice compared to apoA-IHEM and apoA-IWT
mice, the differences in genotypes used in each of these
studies may contribute to some of the differences in the
findings. Nonetheless, our observations support the hy-
pothesis that plasma HDL acts to protect cerebral vessels
not only from Aβ deposition but also from Aβ-induced
astrocyte reactivity.
The mechanisms by which circulating HDL can reduce
amyloid pathology and neuroinflammation are not com-
pletely understood but may include effects of apoA-I
within the brain and effects of HDL/apoA-I from the
periphery. ApoA-I has been shown to enter the brain par-
enchyma of mice via the blood-CSF barrier at the choroid
plexus [55]. ApoA-I that has crossed into the brain may
thus have direct anti-inflammatory effects on astrocytes
consistent with apoA-I’s anti-inflammatory effects on
other cell types [56, 57] or may reduce Aβ-induced in-
flammation by inhibiting Aβ fibrillization as has been ob-
served in vitro [17]. Alternatively, HDL may exert its
effects on the brain indirectly through actions on the cere-
brovasculature, where it would act from the lumen of
cerebral vessels on cells of the neurovascular unit without
crossing into the brain parenchyma. The latter explan-
ation appears more plausible for several reasons. First, the
levels of apoA-I observed within the brain are low com-
pared to the levels found circulating in the blood (ELISA
and immunoblot levels of apoA-I in brain interstitial fluid
are < 0.005% of plasma levels) [55]. Second, HDL has
multiple vasoprotective properties including anti-inflam-
matory activity, modulation of vessel tone, and promotion
of endothelial cell repair [58]. Third, HDL has Aβ-specific
vasoprotective functions in 3D bioengineered human ar-
teries including preventing vascular Aβ accumulation and
attenuating Aβ-induced vascular inflammation [16, 17].
Finally, previous work genetically manipulating apoA-I
levels in APP/PS1 mice found changes specifically in vas-
cular amyloid deposition without any changes to paren-
chymal plaques suggesting that the cerebrovasculature is
the most sensitive target of HDL in the brain [34, 37]. As
described above, we observed several vascular-specific
changes in APP/PS1 mice based on apoA-I genotype.
Briefly, we found increased protein levels of PDGFRβ and
ICAM-1 as well as ICAM-1-positive area on endothelial
cells and GFAP-positive astrocytes associated with the cer-
ebrovasculature. That we observed the most prominent
effects of apoA-I in the cortex is also consistent the ana-
tomical location of CAA-susceptible penetrating arteries.
Our observations of increased plaque-associated GFAP
in apoA-IKO APP/PS1 mice suggests an interaction among
Aβ, astrogliosis, and apoA-I. CAA-associated GFAP, but
not vascular GFAP-associated CAA, was significantly ele-
vated in apoA-IKO mice. Therefore, we speculate that the
loss of apoA-I increases the reactivity of astrocytes to
amyloid, as opposed to loss of apoA-I increasing astroglio-
sis first and then leading to increased amyloid deposition
as a result. In other words, the anti-inflammatory effects
of HDL in the brain are working specifically against Aβ. In
support of this hypothesis, loss of apoA-I did not signifi-
cantly affect any neuroinflammatory marker in WT mice,
which do not accumulate Aβ. Others have similarly ob-
served that the elimination of apoA-I is insufficient to ob-
serve pathological vascular changes. For example, apoA-I
deficiency alone does not cause atherosclerosis in mice
even at 15months of age on an atherosclerotic diet,
whereas apoA-I deficiency can worsen the atherosclerotic
pathology of mice lacking LDLR [59]. Interestingly, loss of
apoA-I expression may indeed be sufficient to result in
(See figure on previous page.)
Fig. 6 Loss of apoA-I increases astrocyte reactivity to Aβ plaques and vascular Aβ deposits. GFAP associated with Aβ plaques in the cortex (a, b) and
hippocampus (c, d) was visualized with immunofluorescence and normalized to total area of the region. The association of vascular-specific GFAP (GFAP
co-localized with CD31) with CAA was visualized using immunofluorescence and normalized to total cortical CAA area (e, g) and total vascular GFAP area
(f, g) in the cortex. Representative images are beside (a, c) or below (e, f) graphs. Points represent individual mice, and bars represent mean values. Circles
represent female mice, and squares represent male mice. Yellow closed arrowheads ( ) indicate examples of areas of plaque-associated or CAA-
associated GFAP, and white open arrowheads ( ) indicate examples areas of plaque or CAA not associated with GFAP. Arrowheads in (g) indicate areas
of CAA and vascular GFAP. Results of Mann-Whitney test (a) and unpaired t test (e) are displayed within graphs as *p< 0.05. For plaque and CAA area
associated with GFAP, N= 5–6 mice per genotype were used; for CAA area associated with vascular GFAP, N= 4–5 mice per genotype were used. apoA-I,
apolipoprotein A-I; HEM, hemizygous apoA-I genotype; KO, knockout apoA-I genotype; APP/PS1, transgenic APP/PS1 genotype; GFAP, glial fibrillary acidic
protein; CD31, cluster of differentiation 31; X-34, amyloid stain; CAA, cerebral amyloid angiopathy
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hypothalamic astrogliosis [60]; however, we did not ob-
serve any significant genotype effects on GFAP expression
in the hypothalamus in the current study (Additional file 1:
Figure S6a and b).
If the primary mechanism of action of HDL on
AD-relevant pathologies is through HDL’s peripheral ac-
tivities, increasing circulating HDL may be an attractive
therapeutic approach that may complement anti-amyloid
approaches. Although HDL-based therapeutics have not
yet been studied in humans for their potential benefits
against cognitive decline, several studies have investigated
whether treating vascular risk factors can affect dementia
and AD risk. Indeed, a recent systematic review and
meta-analysis found that using statins to improve lipid
health significantly reduced AD and dementia risk overall
in prospective trials; however, the single RCT performed
did not find any benefits [61].
Future research on HDL-based therapeutic approaches
for AD will benefit from the considerable safety and effi-
cacy data gathered from clinical trials using HDL formula-
tions, including recombinant apoA-I proteins, apoA-I
mimetics, and plasma-derived apoA-I, all of which were
developed to treat atherosclerosis [62, 63]. CER-001 and
MDCO-216 are recombinant proteins of the wildtype and
Milano sequences of apoA-I, respectively, which were
both well tolerated as infusions in phase II clinical trials
but were unsuccessful in meeting the primary endpoint of
reduced atherosclerosis [64–66]. ApoA-I mimetic pep-
tides, such as D-4F and L-4F, were developed to overcome
the production difficulties associated with full-length re-
combinant proteins and improve oral bioavailability. Phase
I and II clinical trials show that D-4F and L-4F are also
well tolerated but ineffective in reducing atherosclerosis
[67, 68]. A more promising therapeutic is CSL-112, a
plasma-derived, reconstituted apoA-I formulation that
was well tolerated in phase I and II clinical trials and
showed early indications of improvements to cholesterol
efflux capacity [69]. Plasma-derived pre-β HDL has also
been tested in an autologous manner whereby delipidated
HDL is infused back into the patient from which it was
obtained, an approach that is well tolerated and tends to
reduce atherosclerosis [70]. Subjects are currently being
recruited for phase III trials for both of these plasma-de-
rived HDL formulations. Direct upregulation of apoA-I
transcription has also been attempted with the small mol-
ecule RVX-208; however, establishing an appropriate dose
to balance efficacy and safety has proven difficult [71, 72].
Despite the mixed data on efficacy in treating atheroscler-
osis, the abundant information on safety and tolerability
in clinical trials is promising for the potential repurposing
of HDL-based therapeutics for AD.
In addition to the potential of HDL as an AD thera-
peutic, HDL may be a valuable tool to prevent or treat the
cerebrovascular adverse effects of other AD therapies.
Anti-Aβ monoclonal antibodies are one of the major drug
types currently in phase II and III clinical trials for AD
[73]. The success of these drugs is still to be determined
through ongoing trials, but it has become clear that
amyloid-related imaging abnormalities (ARIA) [74, 75]
found on MRI indicating cerebrovascular edema are a po-
tential adverse effect. ARIA in anti-Aβ monoclonal anti-
body trials is thought to result from the vascular
accumulation of Aβ42 that is solubilized from plaques by
the therapeutic antibodies and cleared from the brain via
periarterial pathways [76]. The present work showing that
apoA-I reduces vascular Aβ deposition and the recent
work by our group with 3D engineered human arteries
showing that HDL can specifically prevent Aβ42 vascular
accumulation suggests that HDL may be a valuable com-
panion therapeutic to administer in conjunction with
anti-amyloid therapies to prevent or treat ARIA. Our find-
ings also suggest that HDL may be a valuable tool in the
treatment of CAA-related inflammation (CAARI). CAARI
is a form of CAA presenting as an MRI abnormality simi-
lar to ARIA but with an acute onset and the presence of
inflammation and amyloid deposition together [77]. We
showed in the present study that lack of apoA-I exacer-
bates astrocyte reactivity to vascular Aβ; therefore,
HDL-based therapeutics may have a unique ability to
protect against CAARI by suppressing the reactivity of im-
mune cells to CAA.
Our study has several limitations. First, our breeding
strategy was designed to maximize the production of mice
with a total absence of apoA-I rather than produce control
animals with wildtype levels of apoA-I. Nevertheless, our
observation of a robust reduction in HDL-C levels between
apoA-IHEM and apoA-IKO mice is consistent with previous
literature showing that the difference in plasma HDL-C
levels is indeed larger in magnitude between apoA-IHEM
and apoA-IKO mice compared to apoA-IHEM and
apoA-IWT mice. Therefore, we posit that the apoA-IHEM
and apoA-IKO cohorts in this study are sufficient to test
the hypothesis that reducing plasma HDL-C levels worsens
cerebrovascular phenotypes in APP/PS1 mice. Further lim-
itations include use of mixed sexes and analysis at a single
age. It is well known that in humans, females have a higher
risk of AD than males and their disease progresses more
quickly upon diagnosis [78]. Although we were unable to
make statistical comparisons based on sex due to limita-
tions in breeding and survival of animals of each genotype
and sex, male and female mice are distinguished visually in
all of our presented data and no clear sex bias is evident
even though the sex of the mice was not balanced between
groups. Aging is another major risk factor for AD that we
did not extensively investigate, as our study examines mice
at 12months of age when amyloid pathology is well devel-
oped. A technical limitation in this study is our limited in-
vestigation of the interaction of the vasculature, amyloid,
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ICAM-1 and astrogliosis by the method of immunofluor-
escence. While we were conservative in our investigation
by only analyzing amyloid, CD31, ICAM-1 and GFAP that
were completely associated, it is possible that some associ-
ation could arise from the overlap of these markers in dif-
ferent planes due to the z-stack imaging technique used to
visualize the brain sections. A second technical limitation
is that biochemical analysis was only evaluated in crude
half-brain homogenates; therefore, our ability to detect re-
gion-specific changes was limited for biochemical assess-
ments. Finally, our ability to detect significant genotype
effects on memory performance is limited by relatively
small cohorts that survived until analysis.
Despite these limitations, this study makes significant
progress in developing a strong rationale to test HDL as a
therapeutic agent in AD that specifically targets the vascu-
lature. The work by both Lewis et al. and Lefterov et al.
showing that genetic manipulation of apoA-I can specific-
ally affect CAA has not been confirmed since the original
publications in 2010. Our study also expands upon the
role of apoA-I in cerebrovascular health by showing that
loss of apoA-I increases Aβ within the brain and exacer-
bates the potentially pathological reactivity of astrocytes to
vascular and parenchymal Aβ. Some groups have already
begun to evaluate the potential benefits of apoA-I mi-
metics or reconstituted HDL in AD mice and have ob-
served benefits with respect to amyloid pathology, CAA,
and whole brain neuroinflammation [38–41], although
not all studies found significant improvements or reported
data for all of these pathologies. Our current study dem-
onstrates that the investigation of vascular-specific
pathologies, including CAA and cerebrovascular astroglio-
sis, may be critical in future studies using HDL-based
therapeutics to target AD pathology in general and
vascular-specific amyloid pathologies including CAA,
ARIA, and CAARI.
Conclusions
We confirm previous findings that HDL reduces CAA
and neuroinflammation and extend previous work by
showing that HDL specifically prevents cerebrovascular
astrogliosis and astrocyte reactivity to Aβ deposited in
both parenchymal plaques and in the cerebrovascula-
ture. This work furthers our understanding of how HDL
affects brain health, likely through the circulation, and
suggests that targeting systemic HDL may improve cere-
brovascular health in humans to protect against amyloid
and neuroinflammatory pathologies in AD.
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